July 1, 2019
It would be hard to discuss healthcare trends without talking about what this means for the behemoth pharma industry. Recently, new kid on the block digital health has started to turn heads in across this well-established sector with its potential for improving R&D, tracking real-world evidence and even creating a new type of medicine with digital therapeutics.
While digital promises the...
June 24, 2019
Only around 50% of patients with long-term illnesses adhere to their treatment, according to the World Health Organization (WHO).
To help combat this, pharmaceutical giant Pfizer has teamed up with Finnish health tech startup Popit to provide support to people taking rheumatoid arthritis medication.
Pfizer patients will be offered Popit’s adherence solution, which monitors pill-taking with a...
June 14, 2019
ZappRx, a digital specialty prescription and prior authorization platform, has been purchased by EHR vendor Allscripts for an unknown sum. CNBC broke the news yesterday, which MobiHealthNews confirmed with Allscripts.
CNBC’s sources said that the deal’s value did not exceed the total that investors poured into ZappRx, which Crunchbase pegs at $41 million.
Founded in 2012 and based in Boston,...
June 12, 2019
As more stakeholders enter the digital health arena looking to partner, miscommunications and misconceptions are increasingly common. In order to circumvent this potential Tower of Babel problem, collaboration and shared goals are essential, according to speakers on the Pharma Innovation Beyond the Pill panel at Health 2.0 Europe in Helsinki today.
While there are pitfalls in any partnership,...
June 11, 2019
Less than a year after the blockchain-enabled genome sequencing startup's launch, Nebula Genomics is announcing its first pharma partnership with Merck KGaA’s EMD Serono. This early partnership will come in the form of a pilot program.
As part of the deal, EMD Serono will be able to use Nebula’s network of anonymized genomic data. This new pilot is specifically zeroing in on lung cancer patients...
June 5, 2019
Healthcare is in the midst of a digital shift. Artificial intelligence offers physicians providers an new resource when making decisions, new data streams promise hyper-personalized treatments and digital therapeutics evangelists see are hawking the novel treatments as a companion, or even a replacement, to traditional biologic treatments. All in all, it’s a future that hopes to empower the...
June 5, 2019
“Currently health and tech don’t speak the same language,” says Erik Janssen, vice president of innovative solutions neurology at biopharma company UCB.
In order to benefit from the value technology can bring to patients, Janssen believes that pharma must adapt its approach.
While pharma is a heavily-regulated industry which tends to work in siloes, tech companies tend to be much more “...
June 4, 2019
Since it was first announced, fans and critics of the FDA’s Pre-Cert program for medical software developers have mused on the benefits and burdens that might come with participation in the experimental program.
What to expect from Pre-Cert
The question has only become more pertinent since the agency released its 1.0 Working Model in January and, just a couple weeks ago, began seeking new De Novo...
May 28, 2019
Wearable sensor maker MC10 is teaming up with biopharma company AbbVie on a new set of multiple sclerosis (MS) clinical trials. The pair plan to use MC10’s FDA cleared wearable sensor technology, dubbed the BioStamp nPoint system, to help keep track of a patient’s physiological data and outcomes during the trials.
The flexible and stretchable electronic sensors landed FDA clearance last year to...
(Left to right) Nathan Treloar, Sarah Lindenauer and Matteo Lai at the MassBio panel in Cambridge, MA.
May 22, 2019
Virtual assistants and wearable technologies are starting to catch the pharma world’s attention. The industry is exploring how the new tools can be used in research, clinical trials and inpatient settings. However, obstacles including privacy compliance and data standards are still questions that the industry is grappling with, according to panelists at the MassBio forum on Using Clinical Data...